文献速递皮肤肿瘤

阿司匹林与叶酸预防结直肠腺瘤随机临床试验中的基底细胞癌风险

Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas.
PubMed 文献 · Br J Dermatol · 2018-06-19

在1121例有结直肠腺瘤史者中开展的随机双盲安慰剂对照试验评估阿司匹林和/或叶酸对基底细胞癌(BCC)风险的影响。958例非西班牙裔白人参与者中104例确诊BCC,中位随访13.5年;任何阿司匹林HR 1.45(95%CI 0.93-2.26),叶酸HR 0.85(95%CI 0.57-1.27),均无统计学显著影响。亚组分析提示非甾体抗炎药的化学预防作用可能仅见于BCC高危者。

要点

  • 阿司匹林(81mg或325mg/日)与叶酸(1mg/日)对BCC风险均无统计学显著影响
  • 有既往皮肤癌者阿司匹林与BCC风险降低相关,无既往皮肤癌者风险升高(交互P=0.02/0.03)
  • 亚组分析提示非甾体抗炎药的化学预防作用可能仅见于BCC高危人群

核心结论

  • 阿司匹林或叶酸治疗对基底细胞癌风险均无统计学显著影响。
  • 亚组分析提示非甾体抗炎药的化学预防作用可能仅见于BCC高危者。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,评估阿司匹林(81mg/日或325mg/日,约3年)和/或叶酸(1mg/日,约6年)预防结直肠腺瘤。
  • 共1121例有既往腺瘤史的参与者;BCC经盲法病理报告复核确认。
  • BCC分析纳入958例非西班牙裔白人参与者,中位随访13.5年。

主要发现

  • 958例非西班牙裔白人参与者中104例确诊BCC。
  • BCC累积发生率:安慰剂组12%(95%CI 7-17),阿司匹林81mg/日组16%(95%CI 11-21),阿司匹林325mg/日组15%(95%CI 10-20)。
  • 任何阿司匹林 vs 安慰剂HR 1.45(95%CI 0.93-2.26);81mg/日HR 1.57(95%CI 0.96-2.56);325mg/日HR 1.33(95%CI 0.80-2.20),均未达统计学显著。
  • 无既往皮肤癌者阿司匹林与BCC风险升高相关,有既往皮肤癌者阿司匹林与BCC风险降低相关(81mg/日交互P=0.02;325mg/日交互P=0.03)。
  • 叶酸补充与BCC发生率无关(HR 0.85;95%CI 0.57-1.27)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin may reduce the risk of several types of cancer. OBJECTIVES: To evaluate if folic acid is associated with risk of basal cell carcinoma (BCC). METHODS: BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma. BCC was confirmed by blinded review of pathology reports. RESULTS: One hundred and four of 958 non-Hispanic white participants were diagnosed with BCC over a median follow-up of 13·5 years. Cumulative incidence of BCC was 12% [95% confidence interval (CI) 7-17] for placebo, 16% (95% CI 11-21) for 81 mg aspirin daily and 15% (95% CI 10-20) for 325 mg aspirin daily [hazard ratio (HR) for any aspirin 1·45 (95% CI 0·93-2·26); HR for 81 mg daily 1·57 (95% CI 0·96-2·56); HR for 325 mg daily 1·33 (95% CI 0·80-2·20)]. BCC risk was higher with aspirin use in those without previous skin cancer but lower with aspirin use in those with previous skin cancer (Pinteraction = 0·02 for 81 mg aspirin daily; Pinteraction = 0·03 for 325 mg aspirin daily). Folic acid supplementation was unrelated to BCC incidence (HR 0·85; 95% CI 0·57-1·27). CONCLUSIONS: Neither aspirin nor folic acid treatment had a statistically significant effect on risk of BCC. Subgroup analysis suggested that chemopreventive effects of nonsteroidal anti-inflammatory drugs may be specific to those at high risk for BCC.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Passarelli MN, Barry EL, Zhang D, et al. Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. Br J Dermatol. 2018. PMID: 29570772. doi:10.1111/bjd.16571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。